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In science, the important thing is to modify and 
change one’s ideas as science advances.
Herbert Spencer (1820–1903)
The Year of the Rat
After two years of intensive efforts by an
international consortium of researchers, the
Brown Norway rat (Rattus norvegicus) joins
the human and the mouse as the third
mammalian genomic sequence to be com-
pleted. The achievement is expected to
yield important new knowledge about
mammalian evolution and human disease
processes, and should also contribute sig-
nificantly to progress in toxicogenomics.
The project, funded primarily by the
National Human Genome Research Insti-
tute (NHGRI) and the National Heart,
Lung, and Blood Institute (NHLBI), was
conducted by the Rat Genome
Sequencing Project Consortium.
The Human Genome Sequen-
cing Center at Baylor College
of Medicine led the collabora-
tion, assembled the genome,
and coordinated the data and
resource contributions of a
large network of academic and
private research centers. Next,
an international team compris-
ing more than 20 groups in six
countries analyzed the results
vis-à-vis the human and mouse
genomes. The sequence was pub-
lished in the 1 April 2004 issue of
Nature, along with more than 30
papers analyzing the results rela-
tive to the human and mouse
genomes published simultane-
ously in the April 2004 issue of
Genome Research.
The Brown Norway rat has long been
one of the primary models employed in bio-
medical, toxicological, and pharmaceutical
research. “A large number of human dis-
eases are mimicked in the rat model, and
having the genome sequence lets us easily
walk between what we understand in the
physiology and biology in the rat, and
translate that to a better understanding of
human biology and disease processes,” says
Susan Old, associate director of the Clinical
and Molecular Disease Program in the
NHLBI Division of Heart and Vascular
Diseases and a project officer for the
sequencing initiative. She adds, “Our hope
is to improve the health of the individual by
better understanding of the mechanism of
disease, and to develop better therapeutics
and diagnostics. We are going to be able to
do that a lot more effectively than we had
been able to previously.”
The availability of the rat genome
sequence should also have a profound
impact on toxicogenomics. “At the present
time, when we generate expression profiles
that are associated with a particular disease
or genotype, or in response to a toxicant, we
still have difficulty putting together the
story of what genes and what pathways are
being affected, because a lot of the [genes]
represented by features on the DNA micro-
arrays have still not been identified,” says
Helmut Zarbl, a toxicologist at the Fred
Hutchinson Cancer Research Center in
Seattle. Knowing the locations and identi-
ties of all of the genes in the rat genome will
aid toxicogenomicists in their efforts to
accurately characterize their functions—“to
actually put the story together and come up
with the predictive toxicology we’re looking
for,” says Zarbl.
Zarbl’s group uses rat models to search
for genes associated with human breast can-
cer. He says having the sequence in hand
will advance his work as well as toxicoge-
nomics studies of many other complex dis-
eases strongly suspected to be linked to
gene–environment interactions. “By being
able to map some of these complex diseases
in the rat model and find the causal genes,”
he says, “we can then very quickly go to
human studies using comparative sequence
analysis to formulate hypotheses about what
genes are involved in human disease.”
According to Michael Waters, assistant
director of database development at the
NIEHS-based National Center for Toxico-
genomics (NCT), having the sequence will
enhance work being conducted in a variety
of “omics” areas. “We at the NCT are using
microarray technology, but we’re also using
proteomics, and we want to be able to use
metabolomics to understand how toxicants
operate, what their mode of action is, what
some of the biomarkers are that would
indicate when a toxic outcome is likely to
occur, [and] . . . predict those effects at ear-
lier times and lower doses,” he says. Waters
says the rat genome information provides
the genetic scaffold for scientists to link
expression profiles to a genome that is rele-
vant to toxicology.
With the rat, mouse, and human
genome sequences now completed, com-
parative genomics—identify-
ing the essential functional
and structural components of
the human genome by com-
paring it with the genomes of
other organisms—is posi-
tioned for rapid acceleration.
“Every model organism has its
advantages and disadvantages,
and the more of them that we
have to do experiments in, the
more quickly we’ll be able to
find genes and genotypes
associated with specific phe-
notypes, relate these genotypes
back to the human genome,
and find causes of human dis-
eases,” says Zarbl. 
In August 2004, NHGRI
announced that it has added
18 new model organisms to its
sequencing pipeline, includ-
ing the orangutan, the African savannah ele-
phant, the rabbit, and the domestic cat.
Other groups are working on sequencing
the dog, the cow, the macaque, and several
nonmammalian species. Many of these
projects are expected to be completed with-
in a few years.
Waters anticipates that the flood of
additional genomes will be extremely
valuable to toxicogenomics in two specif-
ic ways. First, he says, the value of exist-
ing databases will be enhanced, with the
cross-species genomic information con-
tributing to chemical risk assessment in
the ecological domain, as well as in
human health. Second, we could possibly
learn far more about basic biological
function in terms of phylogenetic rela-
tionships. –Ernie Hood
Three’s company. The Brown Norway rat joins the human and the mouse as
the third mammal to have its genome fully sequenced.
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Getting to 
the Core of
Antimicrobials
Much research on host defenses against
infection has concentrated on the amino
acid sequences of antimicrobial peptides in
the belief that the order of the acids and their
replication reflect how they work against
aberrant cells. Now researchers at the Uni-
versity of California, Los Angeles, (UCLA)
suggest that the shape the sequences are
arranged in may be a critical part of how
these peptides work. A new report indicates
that host defense systems across the spec-
trum of life rely on a universal core structure
integral to many natural antimicrobial pep-
tides. This core motif may play a key role in
preventing or limiting infection, an insight
that could accelerate a major advancement in
antimicrobial drug development. 
“It has been generally accepted that there
is a wide diversity in amino acid sequences
and sources of antimicrobial peptides,” says
study co-investigator Michael Yeaman, a
professor of medicine at the David Geffen
School of Medicine at UCLA. “But there
hasn’t been as much insight into the similar-
ities that might exist that link all of these
diverse groups of molecules.”
The gamma (γ)-core motif—so called
because it resembles the Greek letter—may
be that missing link, providing a key ingredi-
ent in the signature of antimicrobial pep-
tides. Yeaman and coauthor Nannette Yount,
a molecular biologist at the Los Angeles Bio-
medical Research Institute, say the γ-core
alone can have antimicrobial activity, but
also appears to provide a scaffold on which
critical modules are configured to create
molecules that hunt down microbial
pathogens and destroy them in diverse tissue
contexts without injury to the host.
The duo studied the amino acid se-
quences and three-dimensional structures of
over 500 antimicrobial peptides, and found
the γ-core structure in molecules as diverse as
pea defensins, fruit fly drosomycin, pig pro-
tegrin, and human hepcidin. Such molecules
share the multidimensional signature of
antimicrobial peptides. In a paper published
11 May 2004 in Proceedings of the National
Academy of Sciences, the authors wrote,
“This striking multidimensional signature is
conserved among disulfide-containing
antimicrobial peptides spanning biological
kingdoms, and it transcends motifs previ-
ously limited to defined peptide subclasses.”
But the sequence, composition, and bio-
chemistry of the amino acids that make up
the signature still play a major role, says Yea-
man. “We feel that some of the universality
identified here may have been missed previ-
ously because to identify this signature, we
had to look at amino acid sequences in both
forward and reverse orientation, and that is
not typically done,” he says. “The broad
conservation of the multidimensional signa-
ture identified may have been missed if we
only performed amino acid sequence search-
es and alignments in a conventional way.”
There are other critical aspects of the γ-
core motif as well, Yeaman says. “The amino
acid sequence is configured in three-dimen-
sional space so that the γ-core has certain
characteristics. For example, electrostatic
charge tends to be placed in one part of this
motif and hydrophobicity in another;
disulfide linkages are also conserved. These
hallmark features of the γ-core motif rely
on both composition and three-dimension-
al structure.”
Yeaman and Yount are now translating
the motif into peptide mimetics and small
molecules, and are designing so-called mod-
ular anti-infectives with customized payloads
of drugs that attach to the γ-core motif.
These compounds are at different stages of
development—some are in the design phase,
while some have been tested and proven to
have antimicrobial efficacy. Still others are
being optimized based on data generated in
the lab as well as in initial ex vivo studies.
“We are trying to develop entirely new types
of ‘smart’ antibiotics that recognize and act
against harmful microbes, particularly those
that have become resistant to most all con-
ventional drugs,” Yeaman says.
The work has captured the attention of
researchers in the drug development indus-
try. “It’s the structure that defines the signa-
ture,” says Steve Projan, vice president of
biological technologies at Wyeth Research in
Cambridge, Massachusetts, and a consultant
to the American Society for Microbiology,
based in Washington, D.C. “That structure
may be more important than sequence of
amino acids. Even if the amino acids are dif-
ferent, it is the overall structure that defines
the activity of the molecule.” However,
Projan admits, “I’ll be skeptical about the
impact of this work until we have a molecule
that works by [these] rules and a molecule
that also works in an infection model.” 
Yeaman suggests that learning how
nature has evolved antimicrobial agents may
allow scientists to use the γ-core motif or
mimetics thereof as the scaffold that will
guide the right peptide or molecule to the
right target. “Nature has done much of the
designing,” he says. “We are capitalizing on
the experiments that nature has performed
over millions of years [and] trying to inte-
grate the results of that process in new
antibiotics.” –Ed Susman
MOLECULAR BIOLOGY
Common threads. The γ-core motif, visualized in red above, is seen in antimicrobial peptides from a breadth of organisms, including (left to right)
the scorpion, the human, Aspergillus, the mussel, and the buckeye tree. The motif appears to provide a scaffold upon which disease-fighting mole-
cules are configured.Tackling Innate
Immunity 
According to the 1999 World Health Orga-
nization report Removing Obstacles to
Healthy Development, infectious diseases
cause one-third of all human deaths world-
wide. These diseases also cost the livestock
industry billions of dollars yearly, according
to figures from the U.S. Department of
Agriculture National Center for Animal
Health Surveillance. Infectious diseases are
currently fought largely with vaccines
(which generate so-called adaptive immuni-
ty) and antibiotics. But adaptive immunity
can take months to acquire, and overuse of
antibiotics may promote resistance in bacte-
ria. If researchers with a Canadian project
called Functional Pathogenomics of Muco-
sal Immunity (FPMI) can unlock the genet-
ic mechanisms behind another branch of
immunity—innate immunity—they may
have the key to faster-acting, more effective
medicines by harnessing the body’s rapid-
response agents. Indeed, project scientists
recently identified a highly promising pep-
tide candidate for future immunotherapies. 
FPMI is funded by Genome Canada, a
nonprofit corporation dedicated to advanc-
ing genomics and proteomics to improve
human and animal health. The three-year
project involves groups at the University of
Saskatchewan, the University of British
Columbia, Simon Fraser University, and the
Vancouver firm Inimex Pharmaceuticals. 
“The unique strength of FMPI is the
application of animal and human models of
infection to study evolutionarily conserved
host responses,” says microbiologist Vivek
Kapur, co-director of the Biomedical
Genomics Center at the University of
Minnesota. Because the mechanisms of the
innate immune system are not well under-
stood, this comparative genomics approach
to study host–pathogen interactions may
lead to new immunotherapeutics to prevent
infections, he adds. 
Innate immunity appears highly con-
served in evolution, suggesting that similar
events occur in different species. Innate
immunity is relatively nonspecific and acts
rapidly to block pathogens at the point that
they enter the body: the mucous membranes
of the respiratory, digestive, and reproduc-
tive tracts. Agents produced by the innate
immune system—such as cytokines, chemo-
kines, and natural host defense peptides—
act immediately in response to infection. 
The researchers use microarrays to watch
gene activity in humans and animals follow-
ing exposure to six bacteria and three viruses
associated with hospital-acquired infections,
food poisoning, and livestock illnesses. “If
we can show that the same genetic processes
happen in cows, chickens, and humans, that
gives us a great deal of confidence that we’re
on the right path [to understanding the
mechanism involved],” says project co-
leader Lorne Babiuk, director of the Vaccine
and Infectious Disease Organization at the
University of Saskatchewan.
The data generated by the thousands of
microarray experiments are processed by
bioinformaticists headed by Fiona Brink-
man, an assistant professor of molecular
biology and biochemistry at Simon Fraser
University. The team’s sophisticated software
system, called ArrayPipe, “allows researchers
from distant geographic regions to work
together and view each others’ analyses,”
says Brinkman. The software is available in
an “open source” format that makes it very
flexible and easy to customize. ArrayPipe
can be downloaded for free at http://www.
pathogenomics.ca/arraypipe/.
The genes related to innate immunity
encode disease-fighting substances, which
not only kill pathogens, but also produce
inflammation. Although some inflamma-
tion is necessary to kill pathogens, it can
escalate to undesirable conditions such as
septic shock. One goal of the FPMI
researchers is to find ways to induce desir-
able disease-fighting responses, yet quell
undesirable ones related to inflammation. 
A major breakthrough came when re-
searchers in the laboratory of FPMI co-leader
Bob Hancock, who is director of the Centre
for Microbial Diseases and Immunity
Research at the University of British Colum-
bia, showed that the natural host defense
peptide LL-37 cures infections as it suppress-
es inflammation. In a report published 15
March 2004 in The Journal of Immunology,
Hancock and colleagues write that LL-37
up-regulates genes linked with the inflam-
mation that kills microbes, but down-regu-
lates those linked with the inflammation that
promotes septic shock, suggesting that LL-
37 serves as a watchdog to control inflam-
matory processes. “This . . . indicates that
you can get the good aspects of innate
immunity without the bad,” says Hancock. 
Scientists at Inimex are designing new
drug compounds based on LL-37. The new
strategy will encourage the body’s innate
immune system to attack foreign invaders,
rather than bombard bacteria with antibi-
otics—an approach that increasingly leads
to antibiotic-resistant strains. “It’s a new
perspective that’s desperately needed to
counteract antibiotic-resistant bacteria,”
says Hancock. –Carol Potera
INFECTIOUS DISEASE
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Everybody’s got one. The ability of innate immunity to block pathogens at the mucous membranes appears highly conserved across species.R
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Cellular Jigsaw
Puzzles
Although scientists have great under-
standing of individual molecules, the lim-
itations of modern technology have
restricted the study of molecular group-
ings, or “machines,” within cells. Now,
however, scientists with the Structural
and Computational Biology Programme
at the European Molecular Biology Labo-
ratory (EMBL) in Heidelberg, Germany,
have developed a method to predict and
gain understanding of how molecules
assemble into machines—an advance-
ment with significant potential applica-
tion to toxicogenomics.
Group leader Rob Russell says advances
in the study of functional genomics in
recent years have provided the basis for
knowing what components make up these
molecular machines, even though little is
known about what the structures
look like. This new knowledge
about the makeup of molecular
complexes, combined with
electron microscopy technolo-
gy and computer methods
developed by Russell and
computational biologist Pat-
rick Aloy, provided the
framework for the project.
Russell and Aloy stud-
ied yeast proteins, identify-
ing the components of
hundreds of molecular ma-
chines in these cells. Using
the “tandem affinity purifi-
cation” method developed
at EMBL Heidelberg, they
attached molecular tags to
selected proteins and “went
fishing” for other proteins
in the yeast that would
interact with the bait.
These interactive complex-
es form the basis of protein
networks. 
They liken the process, from that
point on, to that of assembling a jigsaw
puzzle, where the pieces are individual
components of particular machines in
yeast cells. They first divided the compo-
nents into groups containing structural
similarities, then proceeded to look for
recurring patterns of molecular interac-
tions. For example, if two similar mole-
cules in one machine were also found in
another, they were considered likely to fit
together in the same way. 
The scientists looked for those kinds of
relationships and built upward, using
knowledge about how various protein
molecules fit together in one machine to
predict the structure of other machines. In
some cases, they were able to draw three-
dimensional images of machines on their
computer screens. Aloy cautions, however,
that these images are predictions—not
depictions—of structure.
The potential application of the
research at EMBL Heidelberg, which was
conducted in conjunction with the private
German biopharmaceutical
company Cellzome,
may be broad. “If
you know something
about structure,
you know a lot
about how some-
thing works,”
Russell says.
“If you’re con-
fident that
the structure is right, you could conceiv-
ably design chemicals to target particular
types of machines.”
Andrej Sali, a professor at the
University of California, San Francisco,
departments of Biopharmaceutical Sciences
and Pharmaceutical Chemistry, says that
scientists working on structural genomics
have become keenly interested in how pro-
tein assemblies function. “The general
point is that structures of assemblies are
informative about what the function of the
assemblies is and how that function is per-
formed mechanistically—how one might
want to control that function, or modify it,
and perhaps eventually how one could
design new functions,” Sali says. “So, for
these purposes, knowledge of structure is
very helpful.”
Sali says Russell and Aloy’s report of
their research, which appeared in the 26
March 2004 issue of Science, has been
widely read because it presents a new way
to envision molecular structures as systems
that appear in three dimensions, and not
just as individual proteins.
Russell believes that knowledge of
molecular machines is useful
in toxicogenomics because
so much in this science
relies on being able to
understand the relation-
ship between often highly
disparate processes. “For
instance,” he says, “how does
liver hyperplasia arise when one is
taking a drug acting on a particular
kinase? This essentially boils
down to understanding the
relationship between path-
ways in the cell, and certain-
ly a structural perspective on
this can be a great boon.”
Russell says he and his
colleagues have only
begun to scratch the
surface with their work
on the functions of molecular
machines. EMBL Heidelberg,
which is funded by public
research monies from 17
member states, recently
received a grant from the Sixth
Framework Programme of the
European Community (which
funds research, development,
and demonstration activities)
to carry the work to the next
level. Russell says his laboratory
will be working with approximate-
ly 20 other groups in Europe to
embark on a variety of further exper-
iments using tools including electron
microscopy and X-ray crystallography.
“The hope,” he says, “is to do this in more
detail than what we were able to do in the
original paper.”
Although there is obviously much work
left to do to realize the potential of this new
method, the possibilities appear wide open.
“It’s an exciting area,” Russell says. “Our
ultimate goal is to have a kind of dynam-
ically updated view of the cell. . . .
Ultimately, we want a complete picture of
the cell.” –Richard Dahl
Pieces
of the puzzle.
Researchers at EMBL
Heidelberg have devised
a way to apply function-
al genomics to derive
the structure of a molecu-
lar machine within the yeast cell.
Such models may also suggest a potential
mode of interaction between polymerase and
transcription initiation factors.
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Y.F. Leung’s Functional Genomics txgnet
With its sequencing completed in 2003, scientists set their sights on
determining the basic structure and inner workings of the human
genome. This movement has spawned numerous new scientific spe-
cialties that have been supported by the growth of data-generating
technologies. One of these interdisciplinary fields, function-
al genomics, is devoted to linking gene expression to function (or
dysfunction) in cells, organs, and tissue. On his website titled Y.F.
Leung’s Functional Genomics, located at http://genomicshome.com/,
Harvard researcher Yuk Fai Leung sketches out the current state of
this new field of study. 
The homepage of the site is divided into three central sections.
The main section, titled All About Functional Genomics, is an assem-
blage of links to relevant outside resources such as “omics” glos-
saries and the Department of Energy
Genomes to Life program. Also in
this section are pages of resources
for related fields including bioinfor-
matics and proteomics. Leung has
also brought together resources on
the use of chaos and nonlinear
dynamics in genomics, and on the
ethical, legal, and social issues sur-
rounding genomics. A group of links
to institutes and core facilities con-
ducting functional genomics work is
also provided.
Microarray technology has been
crucial to the development of func-
tional genomics. The Microarrays subsection gives an overview of
what exactly these tools are, as described through videos, technolo-
gy reviews, even cartoons, and provides descriptions of all of the var-
ious equipment and technology required to perform this sort of
analysis. The Language & Standard subpage lists links to resources on
communicating results with others within the discipline. Listings of
relevant courses, video seminars, conferences, and workshops are
also available.
The Bioinformatics subsection of the website contains links to
more than 50 databases. This subsection, like the Microarrays sub-
section, also has pages devoted to the language and algorithms
used in bioinformatics as well as data standardization. The Ontology
page has links to resources on the efforts to develop a standard, uni-
versal vocabulary that can be used across the “omics” fields for all
organisms. 
Other subsections are devoted to proteomics and to genome
mapping, complex disease mapping, and linkage analysis. They are
populated much as the other two subsections, with pages of glos-
saries, educational opportunities, calendars, and the like.
This website also has a novel Feature Sections element that bench
scientists will find useful. Leung has put together a microarray soft-
ware comparison featuring 13 primary types of software, including
programs for data preprocessing, analysis, and annotation. The page
for each software type has a definition of the software’s use, sug-
gested readings, and lists of the products available in each category.
Also on offer is a compendium of peer-reviewed journal articles relat-
ed to functional genomics, including a list of biotech business articles.
Leung also provides a reading list of books on functional genomics
topics and an in-depth functional genomics glossary. –Erin E. Dooley
Forum